english.prescrire.org > Spotlight > 100 most recent > Prescrire's yearly review of new drugs and indications in 2014

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent : 1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Spotlight

Prescrire's yearly review of new drugs and indications in 2014

In its annual recap of drugs reviewed over the past year, independent French medical journal Prescrire points to some advances, but many drugs are poorly evaluated, too expensive or more dangerous than useful.

Summary

Three drugs analysed by Prescrire in 2014 provided a significant therapeutic advance for some patients.
In 2014, too many drugs are still best avoided, have undergone minimal evaluation, or are excessively expensive.
Drug regulatory agencies should continue their efforts to improve pharmacovigilance and transparency.

"New drugs and indications in 2014" Prescrire Int 2015; 24 (159): 107-110. (Pdf, free)

Download the full review.
Pdf, free

See also:

Drugs to avoid, in the name
of better patient care:
2015 update
(February 2015)
Free

The Prescrire
Drug Awards for 2014
(February 2015)
Free